FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from UTILISE ...
DecisionDx-SCC test predicts local recurrence and metastasis in high-risk cutaneous squamous cell carcinoma, enhancing personalized treatment decisions. The test categorizes patients into three risk ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback